GLP-1

VITAL-H is a $38 million federally funded trial testing rapamycin, semaglutide, and dapagliflozin in 700–1,000 healthy adults aged 60–65. Here’s what it’s measuring and why it matters.

GLP-1 peptides like semaglutide and tirzepatide show promise beyond weight loss. Explore the emerging longevity, neuroprotection and anti-ageing research findings.